Translational Readthrough of Premature Termination Codons in a Therapeutic Context


Coding sequences are defined between a start and a stop codon. The appearance of a nonsense mutation in a coding sequence creates a premature termination codon (PTC), preventing the correct production of the corresponding protein by interrupting translation and inducing the degradation of the transcript via the nonsense‐mediated mRNA decay (NMD) pathway. Over the past 10 years, there has been considerable interest in the possibility of suppressing in‐frame PTCs for therapeutic purposes. Indeed, some drugs have been shown to promote PTC readthrough by binding to mammalian ribosomes, thereby partially restoring the synthesis of a full‐length protein in cultured mammalian cells and animal models. This translational suppression strategy represents a promising therapeutic approach for genetic diseases and cancers due to a PTC.

Key Concepts

  • The stop codons in humans are UAA, UAG and UGA, and they are recognised by release factors.
  • Near‐cognate tRNA‐binding codons display base pairing for only two of the three bases of the codon.
  • Stop codon readthrough is the process by which the ribosome incorporates a near‐cognate tRNA at the stop codon.

Keywords: stop codon readthrough; ribosome; translation; premature termination codon; genetic diseases

Figure 1. Therapeutic strategy. Readthrough compounds compromise translation termination at PTC, allowing the synthesis of a full‐length protein. The re‐expression of the (hopefully active) full‐length protein counteracts the defects caused by the defective allele.
Figure 2. Schematic diagram of the sites of action of known readthrough inducers. The ribosomal structure used is the yeast 80S ribosome (PBD 4V88). The rRNA is shown in grey, and the ribosomal proteins from the 40S and 60S subunits are shown in orange and yellow, respectively. The upper panel shows a higher magnification for the visualisation of negamycin binding to helix 34 in the ribosome (PDB 4W2I); the lower panel shows a higher magnification for the visualisation of G418 binding to helix 44 in the yeast ribosome (PDB 4U40). For the sake of simplicity, the mRNA and tRNA are not shown.
Figure 3. Distribution of the amino acids inserted at the stop codon during readthrough in yeast. Three amino acids are found at each stop codon.


Alkalaeva EZ, Pisarev AV, Frolova LY, Kisselev LL and Pestova TV (2006) In vitro reconstitution of eukaryotic translation reveals cooperativity between release factors eRF1 and eRF3. Cell 125: 1125–1136.

Allamand V, Bidou L, Arakawa M, et al. (2008) Drug‐induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes. Journal of Gene Medicine 10: 217–224.

Amrani N, Dong S, He F, et al. (2006a) Aberrant termination triggers nonsense‐mediated mRNA decay. Biochemical Society Transactions 34: 39–42.

Amrani N, Sachs MS and Jacobson A (2006b) Early nonsense: mRNA decay solves a translational problem. Nature Reviews Molecular Cell Biology 7: 415–425.

Auld DS, Lovell S, Thorne N, et al. (2010) Molecular basis for the high‐affinity binding and stabilization of firefly luciferase by PTC124. Proceedings of the National Academy of Sciences of the United States of America 107: 4878–4883.

Barton‐Davis ER, Cordier L, Shoturma DI, Leland SE and Sweeney HL (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. Journal of Clinical Investigation 104: 375–381.

Bertram G, Bell HA, Ritchie DW, Fullerton G and Stansfield I (2000) Terminating eukaryote translation: domain 1 of release factor eRF1 functions in stop codon recognition. RNA 6: 1236–1247.

Bidou L, Hatin I, Perez N, et al. (2004) Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Therapy 11: 619–627.

Blanchet S, Cornu D, Argentini M and Namy O (2014) New insights into the incorporation of natural suppressor tRNAs at stop codons in Saccharomyces cerevisiae. Nucleic Acids Research 42: 10061–10072.

Blanchet S, Rowe M, Von der Haar T, et al. (2015) New insights into stop codon recognition by eRF1. Nucleic Acids Research 43: 3298–3308.

Bonetti B, Fu L, Moon J and Bedwell DM (1995) The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. Journal of Molecular Biology 251: 334–345.

Brown A, Shao S, Murray J, Hegde RS and Ramakrishnan V (2015) Structural basis for stop codon recognition in eukaryotes. Nature 524: 493–496.

Bulygin KN, Khairulina YS, Kolosov PM, et al. (2011) Adenine and guanine recognition of stop codon is mediated by different N domain conformations of translation termination factor eRF1. Nucleic Acids Research 39: 7134–7146.

Cosson B, Couturier A, Chabelskaya S, et al. (2002) Poly(A)‐binding protein acts in translation termination via eukaryotic release factor 3 interaction and does not influence [PSI(+)] propagation. Molecular and Cellular Biology 22: 3301–3315.

Dranchak PK, Di Pietro E, Snowden A, et al. (2011) Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. Journal of Cellular Biochemistry 112: 1250–1258.

Du M, Jones JR, Lanier J, et al. (2002) Aminoglycoside suppression of a premature stop mutation in a Cftr−/− mouse carrying a human CFTR‐G542X transgene. Journal of Molecular Medicine (Berlin) 80: 595–604.

Du M, Liu X, Welch EM, et al. (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR‐G542X nonsense allele in a CF mouse model. Proceedings of the National Academy of Sciences of the United States of America 105: 2064–2069.

Du L, Jung ME, Damoiseaux R, et al. (2013) A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. Molecular Therapy 21: 1653–1660.

Floquet C, Deforges J, Rousset JP and Bidou L (2011) Rescue of non‐sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Research 39: 3350–3362.

Floquet C, Hatin I, Rousset JP and Bidou L (2012) Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin. PLoS Genetics 8: e1002608.

Howard M, Frizzell RA and Bedwell DM (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine 2: 467–469.

Ito K, Frolova L, Seit‐Nebi A, et al. (2002) Omnipotent decoding potential resides in eukaryotic translation termination factor eRF1 of variant‐code organisms and is modulated by the interactions of amino acid sequences within domain 1. Proceedings of the National Academy of Sciences of the United States of America 99: 8494–8499.

Kayali R, Ku JM, Khitrov G, et al. (2012) Read‐through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Human Molecular Genetics 21: 4007–4020.

Keeling KM and Bedwell DM (2002) Clinically relevant aminoglycosides can suppress disease‐associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. Journal of Molecular Medicine (Berlin) 80: 367–376.

Kerem E, Hirawat S, Armoni S, et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372: 719–727.

Kerem E, Konstan MW, De Boeck K, et al. (2014) Ataluren for the treatment of nonsense‐mutation cystic fibrosis: a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet Respiratory Medicine 2: 539–547.

Kryuchkova P, Grishin A, Eliseev B, et al. (2013) Two‐step model of stop codon recognition by eukaryotic release factor eRF1. Nucleic Acids Research 41: 4573–4586.

Le Hir H, Izaurralde E, Maquat LE and Moore MJ (2000) The spliceosome deposits multiple proteins 20–24 nucleotides upstream of mRNA exon‐exon junctions. EMBO Journal 19: 6860–6869.

Lee HL and Dougherty JP (2012) Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacology & Therapeutics 136: 227–266.

Linde L and Kerem B (2008) Introducing sense into nonsense in treatments of human genetic diseases. Trends in Genetics 24: 552–563.

Malik V, Rodino‐Klapac LR, Viollet L, et al. (2010) Gentamicin‐induced readthrough of stop codons in Duchenne muscular dystrophy. Annals of Neurology 67: 771–780.

Manuvakhova M, Keeling K and Bedwell DM (2000) Aminoglycoside antibiotics mediate context‐dependent suppression of termination codons in a mammalian translation system. RNA 6: 1044–1055.

McElroy SP, Nomura T, Torrie LS, et al. (2013) A lack of premature termination codon read‐through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biology 11: e1001593.

Mullard A (2014) EMA reconsiders 'read‐through' drug against Duchenne muscular dystrophy following appeal. Nature Biotechnology 32: 706.

Namy O, Hatin I and Rousset JP (2001) Impact of the six nucleotides downstream of the stop codon on translation termination. EMBO Reports 2: 787–793.

Namy O, Rousset JP, Napthine S and Brierley I (2004) Reprogrammed genetic decoding in cellular gene expression. Molecular Cell 13: 157–168.

Olivier NB, Altman RB, Noeske J, et al. (2014) Negamycin induces translational stalling and miscoding by binding to the small subunit head domain of the Escherichia coli ribosome. Proceedings of the National Academy of Sciences of the United States of America 111: 16274–16279.

Polikanov YS, Szal T, Jiang F, et al. (2014) Negamycin interferes with decoding and translocation by simultaneous interaction with rRNA and tRNA. Molecular Cell 56: 541–550.

Preis A, Heuer A, Barrio‐Garcia C, et al. (2014) Cryoelectron microscopic structures of eukaryotic translation termination complexes containing eRF1‐eRF3 or eRF1‐ABCE1. Cell Reports 8: 59–65.

Roy B, Leszyk JD, Mangus DA and Jacobson A (2015) Nonsense suppression by near‐cognate tRNAs employs alternative base pairing at codon positions 1 and 3. Proceedings of the National Academy of Sciences of the United States of America 112: 3038–3043.

Sermet‐Gaudelus I, Renouil M, Fajac A, et al. (2007) In vitro prediction of stop‐codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Medicine 5: 5.

Shalev M and Baasov T (2014) When proteins start to make sense: fine‐tuning aminoglycosides for PTC suppression therapy. Medicinal Chemical Communications 5: 1092–1105.

Taguchi A, Nishiguchi S, Shiozuka M, et al. (2012) Negamycin analogue with readthrough‐promoting activity as a potential drug candidate for duchenne muscular dystrophy. ACS Medicinal Chemistry Letters 3: 118–122.

Urban C and Beier H (1995) Cysteine tRNAs of plant origin as novel UGA suppressors. Nucleic Acids Research 23: 4591–4597.

Welch EM, Barton ER, Zhuo J, et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87–91.

Zhouravleva G, Frolova L, Le Goff X, et al. (1995) Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO Journal 14: 4065–4072.

Further Reading

Bidou L and Allamand V (2010) Nonsense mutations causing inherited diseases: therapeutic approaches. In: Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0022433.

Bordeira‐Carrico R, Pego AP, Santos M and Oliveira C (2012) Cancer syndromes and therapy by stop‐codon readthrough. Trends in Molecular Medicine 18: 667–678.

Keeling KM, Xue X, Gunn G and Bedwell DM (2014) Therapeutics based on stop codon readthrough. Annual Review of Genomics and Human Genetics 15: 371–394.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Bidou, Laure, Sandra, Blanchet, and Olivier, Namy(Feb 2016) Translational Readthrough of Premature Termination Codons in a Therapeutic Context. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0024623]